SCHEMBL3313145

SCHEMBL3313145

CCOC(=O)C(C)N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
POLB P06746 1/20 0.55
RAB9A P51151 1/20 0.55
ATM Q13315 1/20 0.55
KDM4E B2RXH2 2/20 0.52
HPGD P15428 1/20 0.52
HTT P42858 1/20 0.52
LMNA P02545 2/20 0.51
MAPK1 P28482 2/20 0.51
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.50
PRMT1 Q99873 1/20 0.50
PKM P14618 1/20 0.50
SIGMAR1 Q99720 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3310151 0.87 ATM (0.56) ALDH1A1MEN1KMT2APOLBATM
SCHEMBL9308762 0.84 ALDH1A1 (0.53) ALDH1A1MEN1KMT2APOLBATM
SCHEMBL8913587 0.84 ATM (0.52) ALDH1A1MEN1KMT2APOLBATM
SCHEMBL11070624 0.82 ALDH1A1 (0.62) ALDH1A1MEN1KMT2APOLBRAB9A
SCHEMBL9308521 0.82 MEN1 (0.58) ALDH1A1MEN1KMT2APOLBATM
SCHEMBL5519020 0.81 ALDH1A1 (0.61) ALDH1A1MEN1KMT2APOLBRAB9A
SCHEMBL6750641 0.81 OPRM1 (0.54) ALDH1A1SIGMAR1
SCHEMBL5551344 0.80 ALDH1A1 (0.56) ALDH1A1MEN1KMT2APOLBRAB9A
SCHEMBL25409382 0.80 GAA (0.49) ALDH1A1MEN1KMT2AATMKDM4E
SCHEMBL17892122 0.80 ATM (0.55) ALDH1A1MEN1KMT2APOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010049731-A1 PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-05-06 WO disclosed
US-20100105655-A1 NOVEL COMPOUNDS 515 ASTRAZENECA AB 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105655-A1 NOVEL COMPOUNDS 515 TYMS, ABCG2, UMPS ALDH1A1 649/4885MEN1 3480/4885KMT2A 3784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.